Dr. Joseph Kozikowski will present on the use of nanoscale molecular imaging in translational medicine at Novartis research headquarters.
NATICK, MA – May 1, 2007 – Clinivation, Inc. announced today that clinivation Founder and CEO Joseph Kozikowski, M.D. will present to research and executive leadership at Novartis Institutes for Biomedical Research.
As an authority on the development and commercialization of advanced medical technology, Dr. Kozikowski will share his perspectives in a presentation entitled “Optimizing Development: Translational Validation of Breast Cancer Targets” on May 14, 2007.
The presentation will address Dr. Kozikowski’s translational research in nanoscale molecular imaging and cancer as Chief Medical Officer and Study Medical Director of ART Advanced Research Technologies Inc. (Technoparc Saint-Laurent, CAN).
Quotes & Commentary:
“It is an honor to have been invited to present, and I thank the Novartis executive leadership for their efforts in arranging this opportunity for learning,” said clinivation Founder and CEO Joseph Kozikowski, M.D.
About Novartis Institutes for Biomedical Research:
The Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical research organization of Novartis. With approximately 6 000 scientists and physicians around the world, our research is focused on discovering innovative new drugs that will change the practice of medicine. We have an open and entrepreneurial culture, encouraging collaboration to make effective therapies.
